Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IGM Biosciences Inc (IGMS)
NASDAQ:IGMS
Holding IGMS?
Track your performance easily
IGMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.72 - $22.50
Previous Close$8.89
Volume276.12K
Average Volume (3M)304.37K
Market Cap
$528.64M
Enterprise Value$355.71M
Total Cash (Recent Filing)$218.79M
Total Debt (Recent Filing)$45.86M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Mar 27, 2025EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.65
Shares Outstanding59,464,181
10 Day Avg. Volume295,776
30 Day Avg. Volume304,370
Standard Deviation0.30
R-Squared0.00114
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)7.34
Price to Sales (P/S)236.17
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue309.85
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.64
Forecast
1Y Price Target
$20.11Price Target Upside126.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
IGM Biosciences News
PremiumCompany Announcements
IGM Biosciences Shifts Focus to Autoimmunity
PremiumCompany Announcements
IGM Biosciences Shifts Focus to Autoimmunity, Appoints New CEOBulls Say, Bears Say
Bulls Say
Financial PerformanceCash sufficient to support operations into 2027.
LeadershipThe appointment of Mary Beth Harler as the new CEO brings leadership with extensive experience in immunology and fibrosis development.
Strategic FocusIGM Biosciences is shifting its focus to autoimmune diseases, which are highly validated areas for their new drug imvotamab.
Bears Say
Clinical TrialsManagement no longer has conviction that a pivotal trial with this asset in colorectal cancer will succeed.
Financial PerformanceIGM Biosciences recorded a net loss of $0.79 per share—significantly wider than the original estimated net gain of $0.21 per share; the difference is attributed to lower-than-anticipated collaboration revenue.
Strategic FocusSanofi has clearly shifted focus on I&I, as pulling away from early stage oncology investments, evident by planned divesture of Amunix and closure of Kiadis.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IGMS FAQ
What was IGM Biosciences Inc’s price range in the past 12 months?
IGM Biosciences Inc lowest stock price was $4.72 and its highest was $22.50 in the past 12 months.
What is IGM Biosciences Inc’s market cap?
Currently, no data Available
When is IGM Biosciences Inc’s upcoming earnings report date?
IGM Biosciences Inc’s upcoming earnings report date is Mar 27, 2025 which is in 123 days.
How were IGM Biosciences Inc’s earnings last quarter?
IGM Biosciences Inc released its earnings results on Nov 08, 2024. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.21.
Is IGM Biosciences Inc overvalued?
According to Wall Street analysts IGM Biosciences Inc’s price is currently Undervalued.
Does IGM Biosciences Inc pay dividends?
IGM Biosciences Inc does not currently pay dividends.
What is IGM Biosciences Inc’s EPS estimate?
IGM Biosciences Inc’s EPS estimate is -$0.73.
How many shares outstanding does IGM Biosciences Inc have?
IGM Biosciences Inc has 34,077,198 shares outstanding.
What happened to IGM Biosciences Inc’s price movement after its last earnings report?
IGM Biosciences Inc reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went down -9.325%.
Which hedge fund is a major shareholder of IGM Biosciences Inc?
Among the largest hedge funds holding IGM Biosciences Inc’s share is Baker Bros Advisors LP. It holds IGM Biosciences Inc’s shares valued at 68M.
---
IGM Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.11 (126.21% Upside)
$20.11 (126.21% Upside)
Blogger Sentiment
Neutral
IGMS Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 5.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $130.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.02%
12-Months-Change
Fundamentals
Return on Equity
-132.11%
Trailing 12-Months
Asset Growth
-35.81%
Trailing 12-Months
Company Description
IGM Biosciences Inc
IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.
---
IGMS Earnings Call
Q4 2023
0:00 / 0:00
---
IGMS Stock 12 Month Forecast
Average Price Target
$20.11
▲(126.21% Upside)
Technical Analysis
Best Analysts Covering IGMS
1 Year
1 Year Success Rate
9/19 ratings generated profit
1 Year Average Return
+20.91%
reiterated a buy rating 13 days ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +20.91% per trade.
---